Oblimersen
Alternative Names: Augmerosen; BCL-2 antisense oligonucleotide - Genta; G 3139; GC 3139; Genasense; Oblimersen sodiumLatest Information Update: 15 Jan 2022
At a glance
- Originator University of Pennsylvania
- Developer Genta; Genta (CEASED); National Cancer Institute (USA)
- Class Antineoplastics; Antisense oligonucleotides; Thionucleotides
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-I for Solid tumours in USA (SC)
- 31 Dec 2011 Discontinued - Phase-I/II for Solid tumours in USA (IV)
- 31 Dec 2011 Discontinued - Phase-II for Breast cancer in USA (IV)